Tradestie Institutional Equity Comparison Engine

EQ vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EQ Overall Edge

EQ Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Growth & Margin while SRZN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
EQ 1.5x vs SRZN N/M Fwd P/E
Growth & Margin Winner EQ
Op Margin 0.0% vs -485.4% ยท YoY -52.3% vs +408.6%
Momentum & Technical Winner SRZN
1Y +5.0% vs +110.8% ยท 52W Pos 9% vs 63%
Options & Structure Winner SRZN
UNCLASSIFIED (100th %ile IV) vs CONSOLIDATION (13th %ile IV)
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
1M Return -16.54%
1Y Return +4.95%
Forward P/E 1.5x
Unified AI Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EQ +4.95% SRZN +110.81% Spread: +105.86 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EQ Revenue SRZN Revenue EQ Op. Margin SRZN Op. Margin Margin Edge
FY2022 $20M $10M -393.9% -354.7% SRZN
FY2023 $40M N/A -40.2% N/A EQ
FY2024 $40M $10M -20.1% -239.7% EQ
FY2025 N/A $0M N/A -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EQ (5) vs SRZN (4)
Institutional Metric EQ SRZN Criterion Row Winner
Market Capitalization Scale $92.2M $642.7M Larger Scale SRZN
Trailing P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Forward P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Revenue Growth (YoY) Growth -52.3% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability 0.0% -485.4% Higher Margin EQ
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.0% -62.8% Higher ROE EQ
52-Week Range Position Momentum 9% ($1โ€“$4) 63% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.54ฮฒ ยท 89% Vol 1.29ฮฒ ยท 73% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite EQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EQ vs SRZN Buy Guide
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EQ nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.